Factors associated with choroidal microvascular dropout change.
glaucoma
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
20
01
2022
accepted:
23
06
2022
medline:
25
9
2023
pubmed:
9
7
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
To investigate the factors associated with choroidal microvasculature drop-out (MvD) enlargement detected by optical coherence tomography angiography (OCT-A) in glaucomatous eyes. Ninety-one eyes of 68 primary open-angle glaucoma patients were enrolled. Only eyes with a minimum of four good quality OCT-A and OCT scans of the optic nerve head acquired at least and with a minimum of 2 years follow-up were included. Area and angular circumference of MvD were analysed on en face images. Univariable and multivariable mixed effects models were constructed to identify the factors contributing to MvD area and angular circumference change over time. Peripapillary MvD was detected in 53 (58.2%) eyes at baseline and in an additional 17 (18.6%) eyes during follow-up, whereas MvD was not detected in 21 (23.0 %) eyes during the entire follow-up period. In multivariable analysis, worse baseline visual field (VF) mean deviation (MD) (ß=0.27, 95% CI 0.10 to 0.44, p=0.002), greater intraocular pressure (IOP) fluctuations (ß=0.86, 95% CI 0.24 to 1.48, p=0.007), higher peak IOP (ß=0.17, 95% CI -0.01 to 0.35, p=0.067) and greater number of IOP lowering medications (ß=1.36, 95% CI 0.67 to 2.05, p<0.001) were associated with faster MvD area enlargement. Worse baseline VF MD and greater IOP fluctuation were also associated with significantly faster MvD circumferential enlargement in multivariable models. Greater IOP fluctuation, higher peak IOP, worse baseline VF MD and greater number of glaucoma medications were significantly associated with MvD enlargement in glaucomatous eyes. The identification of factors associated with MvD enlargement may improve our understanding of the role of choroidal vasculature in glaucoma.
Sections du résumé
BACKGROUND/AIMS
To investigate the factors associated with choroidal microvasculature drop-out (MvD) enlargement detected by optical coherence tomography angiography (OCT-A) in glaucomatous eyes.
METHODS
Ninety-one eyes of 68 primary open-angle glaucoma patients were enrolled. Only eyes with a minimum of four good quality OCT-A and OCT scans of the optic nerve head acquired at least and with a minimum of 2 years follow-up were included. Area and angular circumference of MvD were analysed on en face images. Univariable and multivariable mixed effects models were constructed to identify the factors contributing to MvD area and angular circumference change over time.
RESULTS
Peripapillary MvD was detected in 53 (58.2%) eyes at baseline and in an additional 17 (18.6%) eyes during follow-up, whereas MvD was not detected in 21 (23.0 %) eyes during the entire follow-up period. In multivariable analysis, worse baseline visual field (VF) mean deviation (MD) (ß=0.27, 95% CI 0.10 to 0.44, p=0.002), greater intraocular pressure (IOP) fluctuations (ß=0.86, 95% CI 0.24 to 1.48, p=0.007), higher peak IOP (ß=0.17, 95% CI -0.01 to 0.35, p=0.067) and greater number of IOP lowering medications (ß=1.36, 95% CI 0.67 to 2.05, p<0.001) were associated with faster MvD area enlargement. Worse baseline VF MD and greater IOP fluctuation were also associated with significantly faster MvD circumferential enlargement in multivariable models.
CONCLUSION
Greater IOP fluctuation, higher peak IOP, worse baseline VF MD and greater number of glaucoma medications were significantly associated with MvD enlargement in glaucomatous eyes. The identification of factors associated with MvD enlargement may improve our understanding of the role of choroidal vasculature in glaucoma.
Identifiants
pubmed: 35803672
pii: bjo-2022-321157
doi: 10.1136/bjo-2022-321157
pmc: PMC10464525
mid: NIHMS1920147
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1444-1451Subventions
Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019869
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027510
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026574
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: LMZ: National Eye Institute (F), Carl Zeiss Meditec (F), Heidelberg Engineering (F), OptoVue (F, R), Topcon Medical Systems (F, R) Merck (C); Robert N. Weinreb: Allergan (C), Eyenovia (C), Topcon (C), Heidelberg Engineering (F), Carl Zeiss Meditec (F), Konan (F), OptoVue (F), Topcon (F), Centervue (F).
Références
Invest Ophthalmol Vis Sci. 2014 Apr 07;55(4):2228-36
pubmed: 24458154
Biomed Opt Express. 2017 Feb 01;8(3):1306-1318
pubmed: 28663830
Ophthalmology. 2016 Dec;123(12):2509-2518
pubmed: 27769587
Am J Ophthalmol. 2021 Mar;223:205-219
pubmed: 33129811
Ophthalmology. 2001 Nov;108(11):1943-53
pubmed: 11713061
J Glaucoma. 2018 Feb;27(2):189-196
pubmed: 29271810
Am J Ophthalmol. 1995 Jul;120(1):92-102
pubmed: 7611333
J Glaucoma. 2020 Jun;29(6):423-428
pubmed: 32205833
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
JAMA Ophthalmol. 2019 Jul 1;137(7):810-816
pubmed: 31120486
Int Ophthalmol. 2021 Feb;41(2):687-698
pubmed: 33094441
Sci Rep. 2021 Jan 8;11(1):206
pubmed: 33420294
Prog Retin Eye Res. 2002 Jul;21(4):359-93
pubmed: 12150988
Ophthalmology. 2021 Feb;128(2):227-233
pubmed: 32663530
Can J Ophthalmol. 2008 Jun;43(3):281-3
pubmed: 18504463
Eye (Lond). 1997;11 ( Pt 3):371-6
pubmed: 9373479
Ophthalmology. 2008 Jun;115(6):934-40
pubmed: 17936908
Br J Ophthalmol. 2023 Jun;107(6):809-815
pubmed: 35027356
Ophthalmology. 2018 Apr;125(4):588-596
pubmed: 29224927
Am J Ophthalmol. 1976 Aug;82(2):165-74
pubmed: 821347
Ophthalmology. 2018 Jul;125(7):1003-1013
pubmed: 29486903
Ophthalmology. 2007 Nov;114(11):1965-72
pubmed: 17628686
Br J Ophthalmol. 2021 Mar;105(3):387-391
pubmed: 32499329
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
J Glaucoma. 2000 Apr;9(2):134-42
pubmed: 10782622
Am J Ophthalmol. 2019 Apr;200:65-75
pubmed: 30578786
Arch Ophthalmol. 2010 May;128(5):541-50
pubmed: 20457974
Invest Ophthalmol Vis Sci. 1991 Jan;32(1):39-45
pubmed: 1987105
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
Surv Ophthalmol. 1999 Jun;43 Suppl 1:S183-90
pubmed: 10416762
J Glaucoma. 2017 Mar;26(3):216-222
pubmed: 27875487
Am J Ophthalmol. 2018 Apr;188:141-154
pubmed: 29428454
Curr Eye Res. 2013 Dec;38(12):1241-7
pubmed: 23972028
J Glaucoma. 2021 Aug 1;30(8):690-696
pubmed: 33927152
J Glaucoma. 2020 Jan;29(1):39-45
pubmed: 31764577
Ophthalmology. 2008 Jul;115(7):1123-1129.e3
pubmed: 18082889